4 January 2019

Discussing the results of testing Tinagl1, an experimental new protein treatment, on mice with triple negative breast cancer, Grete Brauten-Smith, Clinical Nurse Specialist at Breast Cancer Care, says:

“While early days, this promising study offers fresh hope to women with triple negative breast cancer, who currently have fewer treatment choices than others facing the disease.

“Being diagnosed with breast cancer is devastating, and it is an even tougher blow finding out it won’t respond to hormone therapies – which can help stop cancer coming back or spreading - leaving many on a knife-edge when they finish the treatments on offer right now.

“And with over 8,000 women in the UK set to be diagnosed with triple negative breast cancer during 2019, it is vital more research is carried out to see if similar results are replicated on humans1.

-Ends-

Notes to editors

1. Cumulative total of each UK country invasive breast cancer cases in 2015 was 55,122. Around 15% of all invasive breast cancers in the UK are triple negative.

For further information, please contact:

Georgia Tilley, Press Officer, Breast Cancer Care

020 7960 3360 (out of hours 07702 901 334)

About Breast Cancer Care

When you have breast cancer, everything changes. Time becomes measured in appointments. The next scan. The next results. The next challenge.

At Breast Cancer Care, we understand the emotions, challenges and decisions you face every day. So, from the day you notice something’s not right to the day you begin to move forward, we’ll be here to help you through.

Whether you want to speak to our nurses, download our specialist information or connect with volunteers who have faced what you are facing now, we can help you feel more in control.

For care, support and information from day one, call us free on 0808 800 6000 or visit breastcancercare.org.uk